Recurrent miscarriages in women not fulfilling classification criteria for antiphospholipid antibody syndrome

International Journal of Immunopathology and Pharmacology

Volumn 27, Issue 3, 2014, Pages 429-432

  Proietta, M ^a   Ferrero, S ^b   Ferri, L ^a   Cifani, N ^a   Bruno, G ^a   Del Porto, F ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b Centers for Reproductive Medicine   (Italy)

Author keywords

Antiphospholipid antibodies; Autoimmune diseases; Pregnancy

Indexed keywords

ACETYLSALICYLIC ACID; CARDIOLIPIN ANTIBODY; ENOXAPARIN; HEPARIN; IMMUNOGLOBULIN G ANTIBODY; PHOSPHOLIPID ANTIBODY; BETA2 GLYCOPROTEIN 1; CARDIOLIPIN;

ADULT; ANTIBODY TITER; ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CLINICAL ARTICLE; DISEASE CLASSIFICATION; FEMALE; GENE MUTATION; HUMAN; HYPERHOMOCYSTEINEMIA; PREGNANCY OUTCOME; PREGNANT WOMAN; RECURRENT ABORTION; RETROSPECTIVE STUDY; RISK FACTOR; SPONTANEOUS ABORTION; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS; THROMBOSIS PREVENTION; BLOOD; CLASSIFICATION; IMMUNOLOGY; LETTER; PREGNANCY; PREGNANCY COMPLICATION;

ABORTION, HABITUAL; ADULT; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; BETA 2-GLYCOPROTEIN I; CARDIOLIPINS; FEMALE; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS; RETROSPECTIVE STUDIES;

EID: 84908420463     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463201402700313     Document Type: Article

References (15)

1. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemostasis 2006; 4:295-306.
2. Clark CA, Davidovits J, Spitzer KA, Laskin CA. The lupus anticoagulant: results from 2257 patients attending a high-risk pregnancy clinic. Blood 2013; 122(3):341-7.
3. Benedetto C, Marozio L, Tavella AM, et al. Coagulation disorders in pregnancy: Acquired and inherited thrombophilias. Ann. NY Acad. Sci 2010; 1205:106-17.
4. Kwak-Kim J, Agcaoili MS, Aleta L, et al. Management of women with recurrent pregnancy losses and antiphospholipid antibody syndrome. Am J Reprod Immunol 2013; 69:596-607.
5. Gleicher N, Elkayam U. Preventing congenital neonatal heart block in offspring of mothers with anti-SSA/Ro and SSB/La antibodies: A review of published literature and registered clinical trials. Autoimmun Rev 2013; 12(11):1039-45.
6. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997; 40:1725.
7. Burt TD. Fetal regulatory T cells and peripheral immune tolerance in utero: implications for development and disease. Am J Reprod Immunol 2013; 69(4):346-58.
8. Bradley LA, Palomaki GE, Bienstock J, Varga E, Scott JA. Can Factor V Leiden and prothrombin G2021 OA testing in women with recurrent pregnancy loss result in improved pregnancy outcomes? Results from a targeted evidence-based review. Genet Med 2012; 14:39-50.
9. Pabimger I. Thrombophilia and its impact on pregnancy. Thromb Res 2009; 123:516-21.
10. Kovac M, Mitic G, Mikovic Z, et al. Thrombophilia in women with pregnancy-associated complications: fetal loss and pregnancy-related venous thromboembolism. Gynecol Obstet Invest 2012; 69:233-38.
11. Van Mens TE, Levi M, Middeldorp S. Evolution of Factor V Leiden. Thromb Haemost 2013; 110:23-30.
12. Kovac M, Mikovic Z, Mitic G, Djordjevic V, Mandic V, Rakicevic L, Radojkovic D. Does anticoagulant therapy improve pregnancy outcome equally, regardless of specific thrombophilia type? Clin Appl Thromb/Haemostatsis 2014; 20(2):184-9.
13. DeSancho MT, Berlus N, Christos PJ, Rand J. Risk factors for clinical manifestations in carriers of Factor V Leiden and prothrombin gene mutations. Blood Coagul Fibrinolysis 2010; 21:11-5.
14. Vega-Ostertag ME, Pierangeli SS. Mechanisms of aPL-mediated thrombosis: effects of aPL on endothelium and platelets. Curr Rheumatol Rep 2007; 9:190-7.
15. Afeltra A, Vadacca M, Conti L, et al. Thrombosis in systemic Lupus Erythematosus: Congenital and acquired risk factors. Arthritis Rheum 2005; 3:452-59.